YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better. Strong PEDMARK growth: Second-quarter net product sales rose 78% year over year to $17.1 million, marking the company's seventh consecutive quarter of…
Pills spilling out of a container ©PXHere Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares jumped 7.88% in pre-market trading on Tuesday after the specialty pharmaceutical company reported second-quarter earnings and revenue above analyst…
(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical co…
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 202…
Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companie…
Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better. Fennec Pharmaceuticals said PEDMARK is seeing stronger commercial traction, with first-quarter 2026 revenue reaching a record $15.1 million as the com…
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approxi…
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Comm…
Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our…
Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better. Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operating…
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinic…
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026…
– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals In…
(RTTNews) - The biotech sector has always been a space where science, capital, and sentiment intersect in complex ways. From cautious optimism around breakthrough therapies to concerns over valuation and funding cycles, analyst perspective…
(RTTNews) - Fennec Pharmaceuticals Inc. (FENC) is expanding the clinical reach of its otoprotective therapy PEDMARK as the University of Arizona Cancer Center launches a new investigator-sponsored Phase I/II study evaluating the drug in ad…
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-Wor…
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation…
Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary - Moby Strategic Growth and Operational Transformation Achieved record net product sales of $44.6 million in 2025, a 50% year-over-year increase driven by expanding active patient c…
Adherex Technologies logo Fennec Pharmaceuticals reported record commercial growth for PEDMARK during its fourth quarter and full year 2025 earnings call, highlighting expanding adoption in both new and existing accounts, improved patient…
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fou…
Key Points Solas Capital Management added 460,619 shares of PRMB in the fourth quarter. The quarter-end position value increased by $7.53 million as a result. PRMB now accounts for 4.27% of fund AUM.10 stocks we like better than Primo Bran…
Key Points Solas Capital Management acquired 73,494 shares of Euronet Worldwide in the fourth quarter. The quarter-end position value increased by $5.59 million as a result of the new position. The new holding represents 3.17% of fund AUM,…
On February 17, 2026, Solas Capital Management disclosed a new position in Euronet Worldwide(NASDAQ:EEFT), acquiring 73,494 shares in the fourth quarter. The shares were worth $5.59 million at quarter’s end. What happened According to a Se…
On February 17, 2026, Solas Capital Management, LLC disclosed a new position in Kyndryl(NYSE:KD). What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Solas Capital Management, LLC initiated…
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.15 per share a year ago. These figures are adjusted for non-recurring items.…
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago. These figures are adjusted f…
– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK®…
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cis…
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside chat…
RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fen…
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten registered…
* Fennec Pharmaceuticals (FENC [https://seekingalpha.com/symbol/FENC]) intends [https://seekingalpha.com/pr/20307705-fennec-pharmaceuticals-announces-private-offering-of-common-shares-in-canada]to engage in a non-brokered offering of its c…
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokere…
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten registered…
* Fennec Pharmaceuticals (NASDAQ:FENC [https://seekingalpha.com/symbol/FENC]) stated [https://seekingalpha.com/pr/20307363-fennec-pharmaceuticals-announces-proposed-offering-of-common-shares] on Thursday that it would sell its common share…
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to offer and sell its comm…